Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel: Peripheral T-Cell Lymphoma

Explore the latest updates and expert interviews

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Welcome to The Peripheral T-Cell Lymphoma (PTCL) Channel

VJHemOnc presents The Peripheral T-Cell Lymphoma (PTCL) Channel – a source of video interviews, podcasts and roundtable discussions with top experts on the most exciting and impactful updates in the field of PTCL from major international congresses.

The Peripheral T-Cell Lymphoma Channel covers all key research areas including updates on antibody-drug conjugates, ALK inhibitors, and the use of checkpoint inhibitors.

Duvelisib for R/R PTCL: updates from the PRIMO trial 2:42
Duvelisib for R/R PTCL: updates from the PRIMO trial
Steven Horwitz • 6 Dec 2020
TTI-621 for hematologic malignancies: a Phase I dose escalation and expansion study 2:29
TTI-621 for hematologic malignancies: a Phase I dose escalation and expansion study
Steven Horwitz • 6 Dec 2020
5-year follow-up of ECHELON-2: A+CHP vs CHOP for CD30+ PTCL 2:03
5-year follow-up of ECHELON-2: A+CHP vs CHOP for CD30+ PTCL
Steven Horwitz • 6 Dec 2020
Comparing geriatric screening methods in elderly NHL patients 3:02
Comparing geriatric screening methods in elderly NHL patients
Raúl Córdoba • 22 Jun 2020
T-cell lymphomas: murine models, in-situ treatments & screening for HTLV1 12:31
T-cell lymphomas: murine models, in-situ treatments & screening for HTLV1
David Weinstock et al. • 16 Sep 2019
Hello TELLOMAK: new trial for T-cell lymphoma 1:15
Hello TELLOMAK: new trial for T-cell lymphoma
Pierluigi Porcu • 19 Jul 2019
AATT study final results: allo or auto transplant for consolidation in T-cell lymphoma? 3:24
AATT study final results: allo or auto transplant for consolidation in T-cell lymphoma?
Olivier Tournilhac • 19 Jul 2019
Immunoepigenetic platforms for PTCL treatment 6:47
Immunoepigenetic platforms for PTCL treatment
Owen O'Connor • 2 Jul 2019
The T-cell lymphoma project: prospective data collection changing the world 2:11
The T-cell lymphoma project: prospective data collection changing the world
Massimo Federico • 20 Jun 2019

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Diamond Supporter

AstraZeneca

Gold Supporter

BMS Johnson & Johnson

Silver Supporter

Takeda

Bronze Supporter

Galapagos

If you are interested in becoming a supporter of The Lymphoma Channel, please contact us.

The content of VJHemOnc is intended for healthcare professionals